NCT04412577

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 57 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies.

Conditions

• Relapsed/Refractory Hematological Malignancies

Interventions

Type	Name	Description
DRUG	TQB3473	TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.

Timeline

• Start date: 2020-10-12
• Primary completion: 2021-12-01
• Completion: 2022-06-01
• First posted: 2020-06-02
• Last updated: 2021-04-01

Locations

2 sites across 1 country: China